Abstract
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis. In IgAN, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes. It is not known whether the galactose deficiency in IgA1 proteins occurs randomly or preferentially at specific sites. We have previously demonstrated the first direct localization of multiple O-glycosylation sites on a single IgA1 myeloma protein by use of activated ion-electron capture dissociation (AI-ECD) Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry. Here, we report the analysis of IgA1 O-glycan heterogeneity by use of FT-ICR MS and liquid chromatography FT-ICR MS to obtain unbiased accurate mass profiles of IgA1 HR glycopeptides from three different IgA1 myeloma proteins. Additionally, we report the first AI-ECD fragmentation on an individual IgA1 O-glycopeptide from an IgA1 HR preparation that is reproducible for each IgA1 myeloma protein. These results suggest that future analysis of IgA1 HR from IgAN patients and normal healthy controls should be feasible.
Similar content being viewed by others
References
Julian BA, Waldo FB, Rifai A, Mestecky J (1988) Am J Med 84:129–132
Emancipator SN (1998) In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the kidney. Lippincott-Raven, Philadelphia, pp 479–539
Barratt J, Feehally J (2005) J Am Soc Nephrol 16:2088–2097
Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S (1993) Contrib Nephrol 104:172–182
Novak J, Julian BA, Tomana M, Mestecky J (2001) J Clin Immunol 21:310–327
Renfrow MB, Cooper HJ, Tomana M, Kulhavy R, Hiki Y, Toma K, Emmett MR, Mestecky J, Marshall AG, Novak J (2005) J Biol Chem 280:19136–19145
Tarelli E, Smith AC, Hendry BM, Challacombe SJ, Pouria S (2004) Carbohydr Res 339:2329–2335
Coppo R, Amore A (2004) Kidney Int 65:1544–1547
Allen AC, Bailey EM, Brenchley PEC, Buck KS, Barrat J, Feehally J (2001) Kidney Int 60:969–973
Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K (2001) Kidney Int 59:1077–1085
Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J (1999) J Clin Invest 104:73–81
Julian BA, Novak J (2004) Curr Opin Nephrol Hypertens 13:171–179
Julian BA, Tomana M, Novak J, Mestecky J (1999) Adv Nephrol 29:53–72
Geyer H, Geyer R (2006) Biochim Biophys Acta 1764:1853–1869
Wuhrer M, Deelder AM, Hokke CH (2005) J Chromatogr B Analyt Technol Biomed Life Sci 825:124–133
Carr SA, Huddleston MJ, Bean MF (1993) Protein Sci 2:183–196
Medzihradszky KF (2005) Methods Enzymol 405:116–138
Wang F, Nakouzi A, Angeletti RH, Casadevall A (2003) Anal Biochem 314:266–280
Chalkley RJ, Burlingame AL (2001) J Am Soc Mass Spectrom 12:1106–1113
Itoh S, Kawasaki N, Ohta M, Hayakawa T (2002) J Chromatogr A 978:141–152
Olson FJ, Backstrom M, Karlsson H, Burchell J, Hansson GC (2005) Glycobiology 15:177–191
Liu T, Qian WJ, Gritsenko MA, Camp DG, 2nd, Monroe ME, Moore RJ, Smith RD (2005) J Proteome Res 4:2070–2080
Marshall AG, Hendrickson CL, Jackson GS (1998) Mass Spectrom Rev 17:1–35
Zaia J (2004) Mass Spectrom Rev 23:161–227
Cooper HJ, Håkansson K, Marshall AG (2005) Mass Spectrom Rev 24:201–222
Zubarev RA, Kelleher NL, McLafferty FW (1998) J Am Chem Soc 120:3265–3266
Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF (2004) Proc Natl Acad Sci USA 101:9528–9533
Håkansson K, Chalmers MJ, Quinn JP, McFarland MA, Hendrickson CL, Marshall AG (2003) Anal Chem 75:3256–3262
Håkansson K, Cooper HJ, Emmett MR, Costello CE, Marshall AG, Nilsson CL (2001) Anal Chem 73:4530–4536
Hogan JM, Pitteri SJ, Chrisman PA, McLuckey SA (2005) J Proteome Res 4:628–632
Kjeldsen F, Haselmann KF, Budnik BA, Sorensen ES, Zubarev RA (2003) Anal Chem 75:2355–2361
Haselmann KF, Budnik BA, Olsen JV, Nielsen ML, Reis CA, Clausen H, Johnsen AH, Zubarev RA (2001) Anal Chem 73:2998–3005
Mirgorodskaya E, Roepstorff P, Zubarev RA (1999) Anal Chem 71:4431–4436
Mormann M, Paulsen H, Peter-Katalinic J (2005) Eur J Mass Spectrom (Chichester, Eng) 11:497–511
Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M (2002) Kidney Int 62:465–475
Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J (1997) Kidney Int 52:509–516
Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J (2007) Kidney Int 71:1148–1154
Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, Julian BA, Novak J (2007) Mol Immunol 44:2598–2604
Xu LX, Zhao MH (2005) Kidney Int 68:167–172
Hiki Y, Tanaka A, Kokubo T, Iwase H, Nishikido J, Hotta K, Kobayashi Y (1998) J Am Soc Nephrol 9:577–582
Novak J, Tomana M, Kilian M, Coward L, Kulhavy R, Barnes S, Mestecky J (2000) Mol Immunol 37:1047–1056
Tomana M, Prchal JT, Garner LC, Skalka HW, Barker SA (1984) J Lab Clin Med 103:137–142
Shevchenko A, Tomas H, Havli Sbreve J, Olsen JV, Mann M (2006) Nat Protoc 1:2856–2860
Shevchenko A, Wilm M, Vorm O, Mann M (1996) Anal Chem 68:850–858
Sullivan B, Addona TA, Carr SA (2004) Anal Chem 76:3112–3118
Senko MW, Hendrickson CL, Pasa-Tolic L, Marto JA, White FM, Guan S, Marshall AG (1996) Rapid Commun Mass Spectrom 10:1824–1828
Blakney GT, van der Rest G, Johnson JR, Freitas MA, Drader JJ, Shi SDH, Hendrickson CL, Kelleher NL, Marshall A (2001) in 49th Amer Soc Mass Spectrom Conf on Mass Spectrom Conf on Mass Spectrom & Allied Topics, Chicago, IL
Senko MW, Canterbury JD, Guan S, Marshall AG (1996) Rapid Commun Mass Spectrom 10:1839–1844
Chowdhury SK, Katta V, Chait BT (1990) Rapid Commun Mass Spectrom 4:81–87
Senko MW, Hendrickson CL, Emmett MR, Shi SD-H, Marshall AG (1997) J Am Soc Mass Spectrom 8:970–976
Marshall AG, Verdun FR (1990) Fourier transforms in NMR, optical, and mass spectrometry. A user’s handbook. Elsevier, Amsterdam
Ledford EB, Jr., Rempel DL, Gross ML (1984) Anal Chem 56:2744–2748
Shi SD-H, Drader JJ, Freitas MA, Hendrickson CL, Marshall AG (2000) Int J Mass Spectrom 195/196:591–598
Karnoup AS, Turkelson V, Anderson WH (2005) Glycobiology 15:965–981
Robinson EW, Leib RD, Williams ER (2006) J Am Soc Mass Spectrom 17:1469–1479
Iwase H, Tanaka A, Hiki Y, Kokubo T, Sano T, Ishii-Karakasa I, Hisatani K, Kobayashi Y, Hotta K (2001) Anal Biochem 288:22–27
Odani H, Hiki Y, Takahashi M, Nishimoto A, Yasuda Y, Iwase H, Shinzato T, Maeda K (2000) Biochem Biophys Res Commun 271:268–274
Acknowledgments
The authors thank Monica Stinnett, Stephanie Wall, John P. Quinn, Stacy Hall, Rose Kulhavy, and Rhubell Brown for their excellent technical assistance. We also thank Dr. Kristina Håkansson for helpful discussions. This work was supported by grants from the National Institutes of Health (RR17261, DK61525, DK71802, DK78244, DE13694, DK64400, and DK47322) the National Science Foundation (DMR-00–841730), the University of Alabama at Birmingham, the National High Magnetic Field Laboratory, and Florida State University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Renfrow, M.B., Mackay, C.L., Chalmers, M.J. et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal Bioanal Chem 389, 1397–1407 (2007). https://doi.org/10.1007/s00216-007-1500-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-007-1500-z